Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02696889 · ClinicalTrials.gov registry record · NA

Rejuvenation of Premature Ovarian Failure With Stem Cells

A NA study of Primary Ovarian Insufficiency and Premature Ovarian Failure, sponsored by University of Illinois at Chicago.

Completed
Registry status
NA
Development phase
3
Enrollment target
1
Study location

NCT02696889: Completed NA study of Primary Ovarian Insufficiency and Premature Ovarian Failure, sponsored by University of Illinois at Chicago.

NCT02696889 is a NA study of Primary Ovarian Insufficiency and Premature Ovarian Failure that has completed, run by University of Illinois at Chicago. The registered enrollment target is 3 participants, below the 184-participant average among 3 other Primary Ovarian Insufficiency trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02696889, a NA study of Primary Ovarian Insufficiency and Premature Ovarian Failure, has completed, sponsored by University of Illinois at Chicago.

COMPLETED
Registry status
NA
Development phase
3 participants
Enrollment target
1
Study location

Study Summary

The ROSE-1 study is designed to determine the efficacy of bone marrow derived stem cell therapy on ovarian function recovery in subjects with idiopathic and other types of premature or primary ovarian failure (POF or POI) and low ovarian reserves.

Primary Outcome

Reduction of 50% in FSH values; increase in AMH and Estradiol levels (30%)

Conditions Studied

Primary Ovarian Insufficiency Premature Ovarian Failure Low Ovarian Reserve

Interventions

  • PROCEDURE ROSE-1 Protocol

Study Locations (1)

Illinois

  • University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2016-02-06
Est. Completion 2021-05-06
Phase NA
University of Illinois at Chicago

430 total trials

What the finished NCT02696889 record still lists

NCT02696889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 184-participant average among 3 other Primary Ovarian Insufficiency trials with a reported enrollment target (98% lower).

The record links to 3 conditions, with Primary Ovarian Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which ROSE-1 Protocol is the first listed.

NCT02696889 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT02696889 about?

NCT02696889 is a clinical study titled "Rejuvenation of Premature Ovarian Failure With Stem Cells". The ROSE-1 study is designed to determine the efficacy of bone marrow derived stem cell therapy on ovarian function recovery in subjects with idiopathic and other types of premature or primary ovarian failure (POF or POI) and low ovarian reserves.

What is the current status of trial NCT02696889?

This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2016-02-06. Estimated completion is 2021-05-06.

What conditions does trial NCT02696889 study?

This clinical trial studies the following conditions: Primary Ovarian Insufficiency, Premature Ovarian Failure, Low Ovarian Reserve.

What interventions are being tested in trial NCT02696889?

The interventions under investigation include: ROSE-1 Protocol (PROCEDURE).

Who is sponsoring clinical trial NCT02696889?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02696889 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Primary Ovarian Insufficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02696889, the US trial registry maintained by the National Library of Medicine. NCT02696889 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.